Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | BLM | P54132 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | GMNN | O75496 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | THPO | P40225 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071011 | 1.00 | HPGD (0.52) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7962106 | 0.92 | HPGD (0.49) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7962102 | 0.92 | HPGD (0.49) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7962097 | 0.92 | HPGD (0.49) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4070167 | 0.90 | HPGD (0.52) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4070529 | 0.90 | HPGD (0.57) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4070166 | 0.90 | HPGD (0.52) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4070530 | 0.90 | HPGD (0.57) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3243803 | 0.89 | HPGD (0.51) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3242400 | 0.89 | KMT2A (0.51) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | claimed |
| JP-2007503453-A | — | — | 2007-02-22 | — | — | JP | claimed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | claimed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | claimed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | claimed |
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | HPGD 692/4885ALDH1A1 66/4885MEN1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.